Cargando…

Fracture in clinical studies of tofacitinib in rheumatoid arthritis

BACKGROUND: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). OBJECTIVE: To assess fracture risk in tofacitinib RA clinical trials. DESIGN: Post hoc analysis. METHODS: We analyzed pooled data of phase I/II/III and long-term extension stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hansen, Karen E., Mortezavi, Mahta, Nagy, Edward, Wang, Cunshan, Connell, Carol A., Radi, Zaher, Litman, Heather J., Adami, Giovanni, Rossini, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806361/ https://www.ncbi.nlm.nih.gov/pubmed/36601090 http://dx.doi.org/10.1177/1759720X221142346

Ejemplares similares

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
por: Mortezavi, Mahta, et al.
Publicado: (2023)

Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
por: Karpouzas, George A., et al.
Publicado: (2023)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
por: Dougados, Maxime, et al.
Publicado: (2023)

Use of Tofacitinib in the Context of COVID‐19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases
por: Mortezavi, Mahta, et al.
Publicado: (2021)

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
por: Curtis, Jeffrey R, et al.
Publicado: (2023)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
por: Kim, Joon Wan, et al.
Publicado: (2013)

Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
por: Inanc, Nevsun, et al.
Publicado: (2023)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2023)

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
por: Fleischmann, R, et al.
Publicado: (2016)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
por: Li, Zhan-Guo, et al.
Publicado: (2018)

Precautions before starting tofacitinib in persons with rheumatoid arthritis
por: Swarnakar, Raktim, et al.
Publicado: (2022)

Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis
por: Hamar, A., et al.
Publicado: (2021)

Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies
por: Boyce, Eric G, et al.
Publicado: (2016)

Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis
por: Vacchi, Caterina, et al.
Publicado: (2021)

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
por: Bird, Paul, et al.
Publicado: (2019)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
por: Kremer, Joel M., et al.
Publicado: (2021)

Tofacitinib Citrate for Ulcerative Keratitis in a Patient with Rheumatoid Arthritis
por: Meadow, Philip B., et al.
Publicado: (2014)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2016)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
por: Clowse, Megan E. B., et al.
Publicado: (2016)

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2018)

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
por: Kawalec, Paweł, et al.
Publicado: (2017)

Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experience
por: Madej, Marta, et al.
Publicado: (2019)

Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis
por: Erol, Kemal, et al.
Publicado: (2019)

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
por: Bertoldi, Ilaria, et al.
Publicado: (2021)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
por: Spinelli, Francesca Romana, et al.
Publicado: (2023)

Machine learning to characterize bone biomarkers profile in rheumatoid arthritis
por: Adami, Giovanni, et al.
Publicado: (2023)

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials
por: Landewé, Robert B. M., et al.
Publicado: (2016)

Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
por: Purohit, Vivek S., et al.
Publicado: (2018)

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
por: Winthrop, K L, et al.
Publicado: (2016)

Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App
por: Radin, Massimo, et al.
Publicado: (2022)

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia
por: Deakin, Claire T., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ko1uqjpv7epf4uaqf013faj5hp